3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Neoplasms
2
Breast Neoplasms
2
Pancreatic Neoplasms
1
Heart Failure
1
Cardiotoxicity
1
Atherosclerosis
1
Interventions
Trastuzumab
2
Ivabradine
2
Exercise
2
Echocardiography
2
Bisoprolol
2
salicylhydroxamic acid
1
sacubitril and valsartan sodium hydrate drug combination
1
mitoquinone
1
epicatechin gallate
1
dapagliflozin
1
candesartan
1
Trimetazidine
1
Therapeutics
1
Surveys and Questionnaires
1
Spironolactone
1
Silymarin
1
Secondary Prevention
1
Restraint, Physical
1
Ramipril
1
Radiotherapy
1
Perindopril
1
Neoadjuvant Therapy
1
Nebivolol
1
Hydroxymethylglutaryl-CoA Reductase Inhibitors
1
Fluorouracil
1
Epirubicin
1
Docetaxel
1
Cyclophosphamide
1
Cisplatin
1
Carvedilol
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Cardiotoxicity
×
Hydroxymethylglutaryl-CoA Reductase Inhibitors
×
Clear all
NCT03186404
2022-02-08
SPARE-HF
University Health Network, Toronto
Phase 2
Unknown
112 enrolled